Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Impact of additional cytoreduction following autologous SCT in multiple myeloma

Bone Marrow Transplantation volume 42, pages 259–264 (2008)Cite this article

Abstract

Reported results of high-dose therapy (HDT) reflect the combined effect of initial therapy and HDT. The incremental contribution of HDT is often difficult to analyze with varying degrees of response pre-HDT. Here we analyze results of HDT in patients with measurable disease at transplant, defined as a serum or 24 h urine M protein of >1.0 g per 100 ml and >200 mg per day, respectively. Paraprotein responses were calculated using measurements prior to HDT and the lowest subsequent measurement. A total of 431 patients were studied; 264 (61.3%) transplanted within 1-year of diagnosis. An additional reduction in paraprotein by 50% following HDT was seen in 86% patients; with 129 patients (30%) obtaining a 90% reduction. Patients with at least a 90% reduction had longer time to progression with no overall survival advantage and this was independent of other prognostic factors for decreased risk of progression. This study provides an estimate of the degree of tumor reduction provided by HDT, in addition to that provided by the initial therapy. In this group of patients with measurable disease after initial therapy, HDT therapy leads to complete responses in nearly a quarter of the patients and a 90% reduction in another 7%, an outcome associated with better progression-free survival.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  PubMed  Google Scholar 

  3. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55–65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227–9233.

    Article  CAS  PubMed  Google Scholar 

  4. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131–3136.

    CAS  PubMed  Google Scholar 

  5. Moreau P, Milpied N, Mahe B, Juge-Morineau N, Rapp MJ, Bataille R et al. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999; 23: 1003–1006.

    Article  CAS  PubMed  Google Scholar 

  6. Moreau P, Kergueris MF, Milpied N, Le Tortorec S, Mahe B, Bulabois CE et al. A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. Br J Haematol 1996; 95: 527–530.

    Article  CAS  PubMed  Google Scholar 

  7. Giralt S, Bensinger W, Goodman M, Podoloff D, Eary J, Wendt R et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood 2003; 102: 2684–2691.

    Article  CAS  PubMed  Google Scholar 

  8. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502.

    Article  CAS  PubMed  Google Scholar 

  9. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929–936.

    Article  CAS  PubMed  Google Scholar 

  10. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA . Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382–3387.

    CAS  PubMed  Google Scholar 

  11. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.

    Article  CAS  PubMed  Google Scholar 

  12. Kaplan E, Meier P . Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  13. Cox D . Regression models and life tables. J R Stat Soc 1972; 34: 187–202.

    Google Scholar 

  14. Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman S, Litzow MR et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006; 6: 384–388.

    Article  CAS  PubMed  Google Scholar 

  15. McElwain TJ, Powles RL . High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822–824.

    Article  CAS  PubMed  Google Scholar 

  16. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R . High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298–1301.

    CAS  PubMed  Google Scholar 

  17. McElwain TJ, Selby PJ, Gore ME, Viner C, Meldrum M, Millar BC et al. High-dose chemotherapy and autologous bone marrow transplantation for myeloma. Eur J Haematol Suppl 1989; 51 (Suppl 1989): 152–156.

    CAS  PubMed  Google Scholar 

  18. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J . Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002; 30: 673–679.

    Article  CAS  PubMed  Google Scholar 

  19. Alexanian R, Dimopoulos MA, Delasalle KB, Hester J, Champlin R . Myeloablative therapy for primary resistant multiple myeloma. Stem Cells 1995; 13 (Suppl 2): 118–121.

    PubMed  Google Scholar 

  20. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004; 34: 161–167.

    Article  CAS  PubMed  Google Scholar 

  21. Blade J, Rosinol L, Garcia-Sanz R, Lahuerta J, Hernandez M, Sureda A et al. A PETHEMA study of high-dose therapy/stem cell support (HDT), including tandem transplant, in primary refractory multiple myeloma (MM): identification of two populations with different outcomes. J Clin Oncol (Meeting Abstracts) 2007; 25 (18 Suppl): 8021.

    Google Scholar 

  22. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000; 26: 979–983.

    Article  CAS  PubMed  Google Scholar 

  23. Harousseau J-L, Attal M, Moreau P, Garban F, Facon T, Avet-Loiseau H . The prognostic impact of complete remission (CR) plus very good partial remission (VGPR) in a double-transplantation program for newly diagnosed multiple myeloma (MM). Combined results of the IFM 99 trials. ASH Annual Meeting Abstracts 2006; 108: 3077.

    Google Scholar 

  24. Dingli D, Pacheco JM, Nowakowski GS, Kumar SK, Dispenzieri A, Hayman SR et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 2007; 25: 4933–4937.

    Article  PubMed  Google Scholar 

  25. Lenhoff S, Hjorth M, Turesson I, Westin J, Gimsing P, Wisloff F et al. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica 2006; 91: 1228–1233.

    CAS  PubMed  Google Scholar 

  26. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 2007; 370: 1209–1218.

    Article  CAS  PubMed  Google Scholar 

  27. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731–735.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported in part by Hematologic Malignancies Program, Mayo Clinic CR20 program, ASCO Young Investigator Award, Amgen Oncology Institute Junior Faculty Award (SK) and grants CA93842 and CA10080 from the National Cancer Institute; National Institutes of Health and the Department of Health and Human Services.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA

    S K Kumar, D Dingli, A Dispenzieri, M Q Lacy, S R Hayman, F K Buadi, S V Rajkumar, M R Litzow & M A Gertz

Authors
  1. S K Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Dingli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Dispenzieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Q Lacy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S R Hayman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F K Buadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S V Rajkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M R Litzow
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M A Gertz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S K Kumar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, S., Dingli, D., Dispenzieri, A. et al. Impact of additional cytoreduction following autologous SCT in multiple myeloma. Bone Marrow Transplant 42, 259–264 (2008). https://doi.org/10.1038/bmt.2008.166

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.166

Keywords

This article is cited by

Search

Advanced search

Quick links